Stay updated on Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial page.

Latest updates to the Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange Detected- Added a government funding and operating-status notice and links to official sources; updated version to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check27 days agoChange DetectedUpdate: revision version changed from v3.0.2 to v3.1.0, a metadata/branding update with no substantive content changes.SummaryDifference0.1%

- Check41 days agoChange DetectedPage updated to revision v3.0.2; the previous v3.0.1 tag was removed along with the Back to Top link. No substantive changes to core content or functional data.SummaryDifference0.2%

- Check48 days agoChange DetectedThe page has updated the status of the Peter MacCallum Cancer Centre, Australia, from 'Active, not recruiting' to 'Unknown status'. Additionally, the revision number has changed from v3.0.0 to v3.0.1.SummaryDifference0.9%

- Check56 days agoChange DetectedThe page has been updated to include a new facility name and location, while also removing previous location details and specific medical terms related to Hodgkin lymphoma and treatment options.SummaryDifference3%

- Check70 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hodgkin Lymphoma: Frontline Clinical Trial page.